Bullish Case: Known: LNTH term structure is backwardated but IV slopes down into Jan (room for IV cooling); vol surface inflates puts far more than calls. Inferred: historical return surface’s densest likelihood is for small/moderate gains and mean reversion, so upside can appear after reimbursement/rollout strength. Prior +5–15% beat hasn’t fully materialized (spot ~108). Oracle (LNTH): defined-risk call spreads timed around Aug 21/Sep 18 if Q3 guidance beats (≥10–15%).

Bearish Case: Known: LNTH implied-vol surface is sharply put-skewed (deep puts much higher), and return surface keeps substantial likelihood for negative returns; term structure still shows elevated IV. SPY vol surface looks steadier, so firm-specific catalysts matter more. Inferred: mean reversion can coexist with drift lower if reimbursement/distribution disappoint. Your prior -20% miss/delay branch is only partially validated (price hasn’t collapsed), while Helium’s fitted forecast remains bearish (~-2.5%, corr -0.2). Oracle (LNTH): defined-risk put spreads if Q3 guidance misses (>10%) into Aug 21.

Potential Outcomes:

1. 40%: Q3/rollout & reimbursement disappoint (miss >10%); put-skewed IV stays high → -6% to -12%.
2. 25%: No material news; IV term-structure cools modestly → -2% to +6%.
3. 20%: Guidance beat ≥10–15% or positive reimbursement update → +8% to +15%, IV compress.
4. 15%: New clinical/regulatory/distribution adverse triggers IV spike (deep-put IV >~80) → -18% to -28%.

July 22, 2026